Healthcare Digital’s Post

The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #GlobalPrecisionCancerDiagnostics #CancerCare #EarlyDetection #PersonalizedMedicine #AdvancedDiagnostics #HealthcareInnovation #OncologyResearch #PatientOutcomes #MedicalTechnology #CancerTreatment

#Celltrion secures major supply contracts with #UniHA and #Bretagne, strengthening market leadership in France #Celltrion #Pharmaceuticals #Biosimilars #Healthcare #Innovation #France #UniHA #Bretagne #Remsima #Herzuma #Vegzelma #Omviclone #CTP43 #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification

🚀 Exciting news from Celltrion! 🚀 Celltrion Inc has successfully secured bids to supply three key biopharmaceutical products #Remsima (infliximab), #Herzuma (trastuzumab), and #Vegzelma (bevacizumab) to UniHA, France's largest pharmaceutical procurement group. These biosimilars treat #autoimmunediseases, #breastandgastriccancer, #colorectalcancer, and #nonsmallcelllungcancer. #UniHA controls significant market shares: 30% infliximab, 27% bevacizumab, and 13% trastuzumab. As a result, Celltrion will be the exclusive supplier of these products until June 2027. Additionally, through the #Bretagneprocurementgroup, Celltrion will supply #Herzuma and #Vegzelma until June 2028. Celltrion’s strategy focused on strong relationships with key stakeholders, ESG achievements, and supply stability. The company's #RemsimaSC has also captured a 26% market share, contributing to a combined 76% share for the #Remsima line in France. Looking ahead, Celltrion plans to expand its participation in the French bidding market and strengthen its sales capabilities for newly approved products like #Omviclone (omalizumab) and #CT-P43 (ustekinumab). The company will aggressively participate in upcoming bids and strive for outstanding results to ensure more patients benefit from Celltrion's treatments. #Celltrion #Pharmaceuticals #Biosimilars #Healthcare #Innovation #France #UniHA #Bretagne #Remsima #Herzuma #Vegzelma #Omviclone #CTP43 #Infliximab #Trastuzumab #Bevacizumab #Omalizumab #Ustekinumab #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification For Detailed News: https://lnkd.in/d94c3p4T Follow our page for more industry updates: https://lnkd.in/de5zNWmK

📢Exciting News 📍 Today, Accord Biopharma, Inc. a subsidiary of Intas Pharmaceutical Ltd has gotten the acceptance of its #Biosimilar DMB-3115 which is proposed biosimilar to STELARA ® (ustekinumab) from #USFDA 📌Accord Biopharma, Inc. conducted multi-regional Phase-III clinical trail in patients with plaque psoriasis. The main focus of the study was the rate of change in the Psoriasis Area and Severity Index (PASI) to assess skin symptom improvement. 💊 STELARA®, a Janssen Biotech blockbuster, approved for psoriasis, psoriatic arthritis, Crohn's, and colitis. It raked in $13.9B in U.S. sales in 2022, ranking among top biologics. #Biosimilar #USFDA #ustekinumab #accordbiopharma #Intas https://lnkd.in/eQiVMPst

Did you know? 80% of the top 10 Pharmaceutical companies are increasing their orphan drug portfolios over the next 3 years towards 35% on average for their respective drug portfolios? With Johnson and Johnson (39%), Vertex (98%), and Astrazeneca (36%) leading the way according to the Evaluate industry report. The ESN Cleer Team 🫀 
#capitalcell #cleerhealth #therapeuticscompany #heartfailure #developing #cardiovasculardisease #heartdisease #hearthealth #heartattacks #heart #stroke #blood #diagnosticstreatments
#personalisedmedicine #BiotechInvestment #PharmaPartnerships #OrphanDrug #CardiomyopathyResearch #HealthInnovation #BioTechDevelopment https://lnkd.in/gJbZjvZa

Hi. It's getting very hot in Japan. We've posted a new blog article regarding the sales highlight of Japan's drug market in 2023 as follows: https://lnkd.in/gpFYRYDc We are a part of ELIQUENT Life Sciences that creates an unprecedented assembly of global regulatory leaders, industry experts, and technical specialists - brought together to bridge the spectrum of regulatory challenges across the product lifecycle. The collective capabilities of the united ELIQUENT team enable a comprehensive approach that delivers integrated solutions to support pharmaceutical, biotechnology, medical device, and combination product companies navigating the complex global regulatory landscape. Top Performing Products: Keytruda (Pembrolizumab) reclaimed the top sales position, surpassing Opdivo (Nivolumab), which experienced a 4.2% revenue decline in Q1 2024 due to a 15% price cut in April. Oncology Market Dominance: The oncology market grew by 9.8% to nearly 2 trillion yen, representing 17% of the domestic market. Keytruda led with a 22.5% increase to 164.8 billion yen. Opdivo grew by 3.5% to 164.5 billion yen but fell to second place due to market recalculation impacts. Imfinzi (Durvalumab) posted a 116% growth, reaching 120.7 billion yen, following new cancer indications. Significant Growth in the Following Therapeutic Areas.......

The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #GlobalOvarianCancerDrugsMarket #OvarianCancerTreatment #CancerResearch #PharmaceuticalIndustry #CancerTherapeutics #PersonalizedMedicine #Healthcare #CancerCare #MedicalAdvancements #MarketOutlook

New study reveals concerns over cancer drugs' added benefit and pricing, urging greater transparency and accountability in the pharmaceutical industry. https://lnkd.in/d97-seph . . . . #CancerDrugs #DrugPricing #HealthcareCosts #Pharmaceuticals #EvidenceBasedMedicine #PatientOutcomes #HealthPolicy #MedicalResearch #HealthEquity #DrugAffordability #HealthcareAccess #DrugApproval #Transparency #QualityOfLife #BMJStudy

Novo Nordisk Invests $1.3B in Corvidia Therapeutics to Challenge Bayer's Kerendia Novo Nordisk is investing up to $1.3 billion in KBP Biosciences' phase 3 challenger to Bayer's CKD drug, Kerendia. Novo Nordisk, buoyed by the success of semaglutide sales, is building on its momentum by acquiring KBP's non-steroidal mineralocorticoid receptor antagonist (nsMRA). KBP aims to establish ocedurenone as a distinct player in the market, focusing on its impact on systolic blood pressure for advanced CKD patients. The primary completion of the hypertension trial is expected in September 2024, reflecting Novo Nordisk's strong belief in the drug's potential. This strategic move holds promise for advancing healthcare solutions. If you're interested in continuing to read the full story and want to stay updated with the Latest Pharma News in USA, visit Pharmtales. #pharma #pharmaceutical #pharmtales #latestnews #pharmanews #pharmaceuticalindustry #novonordisk #bayers #drugs #pharmaceuticalcompanies https://lnkd.in/dD6YZXz7

Exciting strides in the pharmaceutical world! Sally Turner’s recent article for Pharmaceutical-Technology explored the most groundbreaking pharmaceutical breakthroughs of 2023 with the valuable insights from Surbhi Gupta, Senior Industry Analyst, Growth Opportunity Analytics – HLS, at Frost & Sullivan. 🌐 From cancer treatments to rare diseases, the pharmaceutical industry is revolutionizing healthcare. Explore the top 10 novel drugs that made headlines. #MedicalAdvancements #PharmaBreakthroughs